Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

Bibliography

• Ansell J, Bergqvist D. Current options in the prevention of thromboembolic disease. Drugs 2004;64:1-5
   PubMed Web of Science ®Google Scholar
• Leadey R. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 2001;1:151-9
   PubMedGoogle Scholar
• Walenga J, Jeske W, Hoppensteadt D, et al. Factor Xa inhibitors: today and beyond. Curr Opin Investig Drugs 2003;4:272-81
   PubMedGoogle Scholar
• Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(Suppl 1):60-4
   PubMed Web of Science ®Google Scholar
• Sinha U, Ku P, Malinowski J. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur J Pharmacol 2000;395:51-9
   PubMed Web of Science ®Google Scholar
• Pinto D, Orwat M, Koch S, et al. Discovery pf 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxyopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro1-H-pyrazaolo{3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-56
   PubMed Web of Science ®Google Scholar
• Schumacher W, Bostwick J, Stewart A, et al. The direct factor Xa inhibitor apixaban produces broad antithrombotic activity with limited effects on bleeding time in rats. Blood (ASH Annual Meeting Abstracts) 2007;110 [Abstract 4005]
   Google Scholar
• Wong P, Watson C, Crain E, et al. Potent antithrombotic activity of apixaban, a direct factor Xa inhibitor, with minimum bleeding time effect in rabbit models of arterial thrombosis and hemostasis [abstract PW-656]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva
   Google Scholar
• Wong P, Crain E, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6(5):820-9
   PubMed Web of Science ®Google Scholar
• Wong P, Crain E, Pinto D, et al. Dose-dependent antithrombotic effects of apixaban, an oral direct factor Xa inhibitor, in prevention and treatment of thrombosis in rabbit models of arteriovenous-shunt and venous thrombosis at doses that preserve hemostasis. Blood (ASH Annual Meeting Abstracts) 2007;110(11) [Abstract 933]
   Google Scholar
• Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1(7):1504-14
   PubMed Web of Science ®Google Scholar
• Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006;22:471-81
   PubMed Web of Science ®Google Scholar
• Luettgen J, Bozarth T, Bozarth J, et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor X1 inhibitor. Blood (ASH Annual Meeting Abstracts) 2006;108(11) [Abstract 4130]
   Google Scholar
• Bauer KA. New anticoagulants: anti IIa vs anti Xa – is one better? J Thromb Thrombolysis 2006;21(1):67-72
   PubMed Web of Science ®Google Scholar
• Wong P, Crain E, Watson C, et al. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 2007;24:43-51
   PubMed Web of Science ®Google Scholar
• Wong P, Watson C, Crain E, et al. Effects of the factor Xa inhibitor apixaban on venous thrombosis and hemostasis in rabbits. Blood 2006;108:275a
   Google Scholar
• He K, He B, Grace J, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 2006;108(11):[abstract 910]
   Google Scholar
• Jones J. BMS-562247: oral study of embryo-fetal development in rats. Bristol-Myers Squibb document. 18 January 2005
   Google Scholar
• Frost C, Yu Z, Moore K. Apixaban, an oral direct Factor Xa inhibitor: multiple-dose safety, pharmokinetics and pharmacodynamics in health volunteers. J Thromb Haemost 2007;5(S1):PM664
   Google Scholar
• Frost C. Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor [poster T2M061]. IXth World Conference on Clinical Pharmacology and Therapeutics; 27 July – 1 August 2008; Quebec City, Canada
   Google Scholar
• Apixaban (BMS-562247). Bristol-Myers Squibb Investigator Brochure. 22 May 2006.
   Google Scholar
• Frost C, Lee L, Li L, et al. Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol 2007;47(9):1196 [Abstract 60]
   Google Scholar
• Wastall P, Nepal S, Frost C, et al. A randomized, blinded, placebo and positive-controlled, crossover study to determine the effect of repeated doses of the factor Xa inhibitor apixaban on the QTc interval [abstract PII-18]. Clin Pharmacol Ther 2008;83(Suppl 1):S48
   Google Scholar
• Lassen M, Davidson B, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-75
   PubMed Web of Science ®Google Scholar
• Alexander JH, Wallentin L. Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: results from the APPRAISE-1 dose guiding trial. Presented at the European Society of Cardiology, 30 August – 3 September, 2008
   Google Scholar
• Savelieva I, Bajpai A, Camm A. Stroke in atrial fibrillation: update on Pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007;39:371-91
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008;31:55-62
   PubMed Web of Science ®Google Scholar
• Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost, 2008 (Epub ahead of Print)
   Google Scholar